Learn About Pulmonary Fibrosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Weill Medical College Of Cornell
Robert Kaner is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in New York, New York. Dr. Kaner has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Acute Interstitial Pneumonia, Hypersensitivity Pneumonitis, Interstitial Lung Disease, Pulmonary Fibrosis, and Endoscopy.
Weill Medical College Of Cornell
Anna Podolanczuk is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in New York, New York. Dr. Podolanczuk has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Lung Transplant.
David Lederer is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in New York, New York. Dr. Lederer and is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, and Lung Transplant.
Summary: The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Summary: Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.